Sorrento Therapeutics now gains rights for Cynviloq in South America

3 May 2015

US late-stage clinical oncology firm Sorrento Therapeutics (Nasdaq: SRNE) says that its fully-owned subsidiary, Igdrasol, has acquired exclusive distribution rights from South Korea’s Samyang Biopharmaceuticals to Cynviloq (marketed as Genexol-PM in South Korea) in South America. Sorrento’s shares gained 14.75% to $10.35 on Friday following the announcement.

Last year Sorrento obtained exclusive rights to Cynviloq (marketed as Genexol-PM in South Korea and other countries) in Australia, Canada and Mexico from Samyang (The Pharma Letter February 11, 2014).

Financial terms of the latest or previous agreements were not disclosed. Sorrento already has exclusive rights from Samyang for Cynviloq in the USA and the 27 countries of the European Union (The Pharma Letter May 14, 2013).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK